1. Home
  2. CABA vs AIV Comparison

CABA vs AIV Comparison

Compare CABA & AIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.63

Market Cap

495.7M

Sector

Health Care

ML Signal

HOLD

Logo Apartment Investment and Management Company

AIV

Apartment Investment and Management Company

HOLD

Current Price

$2.79

Market Cap

435.9M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
CABA
AIV
Founded
2017
1975
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
495.7M
435.9M
IPO Year
2019
1996

Fundamental Metrics

Financial Performance
Metric
CABA
AIV
Price
$2.63
$2.79
Analyst Decision
Strong Buy
Buy
Analyst Count
6
1
Target Price
$14.50
$10.00
AVG Volume (30 Days)
6.7M
1.6M
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
87.41%
EPS Growth
10.26
616.00
EPS
N/A
N/A
Revenue
N/A
$138,486,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.26
$2.73
52 Week High
$4.23
$8.82

Technical Indicators

Market Signals
Indicator
CABA
AIV
Relative Strength Index (RSI) 35.47 25.16
Support Level $2.11 N/A
Resistance Level $3.40 $3.01
Average True Range (ATR) 0.23 0.06
MACD -0.03 0.03
Stochastic Oscillator 4.72 21.43

Price Performance

Historical Comparison
CABA
AIV

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

About AIV Apartment Investment and Management Company

Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment, and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development. Operating, and Other. The development segment consists of properties that are under construction or have not achieved stabilization, as well as land held for development. The operating segment includes residential apartments, communities with apartment homes that have achieved a stabilized level of operations. The other segment includes The Benson Hotel, the company's only hotel. The majority of revenue is gained from the Operating Segment.

Share on Social Networks: